The shares of Glenmark Pharmaceuticals surged 20% on Friday, July 11, to a days high of Rs 2,286 following a landmark $2 billion licensing deal with U.S. pharma giant AbbVie for its cancer drug, ISB 2001.
Indian equity markets opened lower on Friday, influenced by muted Q1 results from TCS and new tariffs imposed by the U.S. on Canada. The Nifty IT index experienced a decline, while Glenmark Pharmaceuticals surged following a licensing agreement. Experts suggest focusing on fairly valued stocks with earnings visibility amid market pressures.